NEW YORK, March 14 - Oxford GlycoSciences and BioInvent International on Thursday said they are partnering for three years to identify, develop, manufacture, and commercialize therapeutic antibodies.
 
Terms of the agreement call for OGS to provide at least five target antigens per year, which it will identify and validate through its proteomics process. BioInvent, in turn, will apply its n-CoDeR phage display library to identify antibodies targeted to those antigens.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.